GANX logo

GANX
Gain Therapeutics Inc

2,621
Mkt Cap
$80.62M
Volume
424,116.00
52W High
$4.34
52W Low
$1.41
PE Ratio
-3.06
GANX Fundamentals
Price
$1.88
Prev Close
$1.89
Open
$1.84
50D MA
$2.16
Beta
1.24
Avg. Volume
563,811.44
EPS (Annual)
-$0.6115
P/B
4.26
Rev/Employee
$0.00
$86.05
Loading...
Loading...
News
all
press releases
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat...
MarketBeat·20d ago
News Placeholder
More News
News Placeholder
HC Wainwright Has Positive Estimate for GANX Q1 Earnings
Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for Gain Therapeutics in a research note issued on Monday, March 30th. HC Wainwright...
MarketBeat·1mo ago
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results
Gain Therapeutics (NASDAQ:GANX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03...
MarketBeat·1mo ago
News Placeholder
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside...
MarketBeat·1mo ago
News Placeholder
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday
Gain Therapeutics (NASDAQ:GANX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...
MarketBeat·1mo ago
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% - What's Next?
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 3.7% - Should You Buy...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...
MarketBeat·2mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock...
MarketBeat·3mo ago
News Placeholder
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·3mo ago
<
1
2
...
>

Latest GANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.